The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands

European Journal of Preventive Cardiology

Volumn 16, Issue 3, 2009, Pages 371-376

  Kok, Linda ^a   Engelfriet, Peter ^a   Jacobs Van Der, Bruggen Monique A M ^a   Hoogenveen, Rudolf T ^b   Boshuizen, Hendriek C ^b   Verschuren, Monique W M ^a  

^a Centre for Prevention and Health Services Research   (United States)

^b National Institute for Public Health and the Environment   (United States)

Author keywords

cardiovascular disease; cardiovascular risk; cost benefit analysis; guideline; hypercholesterolemia; hypertension; primary prevention; Systematic Coronary Risk Evaluation

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HUMAN; INCIDENCE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NETHERLANDS; POPULATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK MANAGEMENT; STROKE;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES RESEARCH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; NETHERLANDS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 70349205899     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328329497a     Document Type: Article

References (40)

1. Vaartjes I, van Dis SJ, Peters RJG, Bots ML. Cardiovascular disease in The Netherlands. In: Vaartjes I, Peters RJG, van Dis SJ, Bots ML, editors. Cardiovascular disease in The Netherlands [in Dutch]. Den Haag: Dutch Heart Foundation; 2006. pp. 9–21.
2. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360.
3. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens 2006; 24: 423–430.
4. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a metaanalysis of randomized controlled trials. Am J Med 2004; 117: 596–606.
5. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BM J 2003; 326: 1423.
6. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340–2346.
7. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640–651.
8. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999; 19: 187–195.
9. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J (Clin Res Ed) 1985; 291: 97–104.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264.
11. Van Dam M, van Wissen S, Kastelein JJ. Declaring war on undertreatment: rationale for an aggressive approach to lowering cholesterol. J Cardiovasc Risk 2002; 9: 89–95.
12. Antikainen R, Moltchanov V, Chukwuma C, Kuulasmaa K, Marques-Vidal P, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA project. Eur J Cardiovasc Prev Rehabil 2006; 13: 13–29.
13. The Dutch Institute for Healthcare Improvement CBO. Dutch Guideline Cardiovascular Risk Management [in Dutch]. Utrecht: CBO; 2006.
14. Treatment and prevention of coronary heart disease by lowering plasma cholesterol levels. Second revision of the Consensus Cholesterol. Behandeling en preventie van coronaire hartziekten door verlaging van de plasmacholesterolconcentratie. Consensus cholesterol tweede herziening. Utrecht: CBO; 1998.
15. Revision Guideline Hypertension. Herziening Richtlijn Hoge bloeddruk. Utrecht/Den Haag: CBO/Nederlandse Hartstichting; 2000.
16. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.
17. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003.
18. Blokstra A, Smit HA, Verschuren WMM. Changes in lifestyle factors and risk factors for chronic diseases with ageing: the Doetinchem Study 1987–2002 [in Dutch]. Bilthoven: Dutch National Institute for Public Health and the Environment; 2006. Report No. 260401003.
19. Smit HA, Verschuren WMM, Bueno-de -Mesquita HB, Seidell JC. The Monitoring Project on Risk Factors for Chronic Diseases (MORGEN-project): general background [in Dutch]. Bilthoven: Dutch National Institute for Public Health and the Environment; 1994. Report No. 263200001.
20. Hofman A, Boerlage PA, Bots ML, den Breeijen JH, de Bruijn AM, Grobbee DE. Prevalence of chronic diseases among elderly people; the Rotterdam Elderly Study [in Dutch]. Ned Tijdschr Geneeskd 1995; 139: 1975–1978.
21. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403–422.
22. van der Linden MW, Westert GP, de Bakker DH, Schellevis FG. The Second Dutch National Survey of General Practice. Symptoms and disorders in the population and in general practice [in Dutch]. Utrecht/Bilthoven: NIVEL/RIVM; 2004.
23. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178–190.
24. Hoogendoorn M, Rutten-van Molken MP, Hoogenveen RT, van Genugten ML, Buist AS, Wouters EF, et al. A dynamic population model of disease progression in COPD. Eur Respir J 2005; 26: 223–233.
25. Van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metr 2006; 4: 14.
26. Scheltens T, Verschuren WMM, Boshuizen HC, Hoes AW, Zuithoff NP, Bots ML, et al. Estimation of cardiovascular risk: a comparison between the Framingham and the SCORE model in people under 60 years of age. Eur J Cardiovasc Prev Rehabil 2008; 15: 562–566.
27. Van Baal PHM, Feenstra TL, Hoogenveen RT, de Wit GA. Cost effectiveness analysis with the RIVM Chronic Disease Model. Bilthoven: Dutch National Institute for Public Health and the Environment; 2005. Report No. 260706002.
28. Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Costs of Illness Studyin The Netherlands [in Dutch]. Bilthoven: Dutch National Institute for Public Health and the Environment; 2002.
29. Melse JM, Essink-Bot ML, Kramers PG, Hoeymans N. A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. Am J Public Health 2000; 90: 1241–1247.
30. Health Care Insurance Board. Guidelines for Farmaco-Economic Evaluations, Actualised Version [in Dutch]. Diemen; College voor zorgverzekeringen (Health Care Insurance Board): 2006.
31. Casparie AF, van Hout BA, Simoons ML. Guidelines and costs [in Dutch]. Ned Tijdschr Geneeskd 1998; 142: 2075–2077.
32. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–1278.
33. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–1419.
34. Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, de Wit AG, Hofman A, Trienekens PH, et al. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam Study. Drugs Aging 2006; 23: 733–741.
35. Heart Protection Study Collaborative. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. BM J 2006; 333: 1145.
36. Mantel-Teeuwisse AK, Goettsch WG, Klungel OH, de Boer A, Herings RM. Long term persistence with statin treatment in daily medical practice. Heart 2004; 90: 1065–1066.
37. Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005; 59: 564–573.
38. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458–1462.
39. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455–461.
40. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23: 2101–2107.